Clinical trial results:
A Phase II Multicenter, Randomized, Double-blind, Placebo controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX-0061 Administered Subcutaneously in Subjects with Moderate to Severe Active Systemic Lupus Erythematosus

Summary

EudraCT number	2015-000372-95
Trial protocol	CZ DE PT HU ES
Global end of trial date	25 January 2018

Results information

Result version number	v1 (current)
This version publication date	01 December 2018
First version publication date	01 December 2018

Trial information

Trial identification

Sponsor protocol code	ALX0061-C204

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02437890
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Ablynx NV
Sponsor organisation address	Technologiepark 21, Zwijnaarde, Belgium, 9052
Public contact	Medical Monitor, Ablynx, +32 (0)9 262 00 00, clinicaltrials@ablynx.com
Scientific contact	Medical Monitor, Ablynx, +32 (0)9 262 00 00, clinicaltrials@ablynx.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	08 March 2018
Is this the analysis of the primary completion data?	Yes
Primary completion date	25 January 2018
Global end of trial reached?	Yes
Global end of trial date	25 January 2018
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To assess the efficacy and safety of different dose regimens of ALX-0061 administered subcutaneously (s.c.) to subjects with moderate to severe active, seropositive systemic lupus erythematosus (SLE) compared to placebo.

Protection of trial subjects:

Only subjects who met all the study inclusion criteria and none of the exclusion criteria were to be randomized to study treatment. All subjects were free to withdraw from the clinical study at any time for any reason. Close monitoring of all subjects was to be adhered to throughout the study.

Background therapy:

Standard of care therapy for SLE. The dose of oral corticosteroids (equivalent to ≤25 mg of prednisone/day) was to be stable for at least 4 weeks prior to baseline. If the subject had started immunosuppressants prior to first dosing and was still taking this medication at baseline: azathioprine (maximum 150 mg/day), mycophenolate mofetil (maximum 2.0 g/day), methotrexate (MTX) (maximum 25 mg/week), cyclosporine (maximum 200 mg/day), leflunomide (maximum 20 mg/day), treatment duration had to be at least 12 weeks with a stable dose for at least 4 weeks prior to baseline; either alone or in combination with corticosteroids and/or hydroxychloroquine.

Evidence for comparator:

Not applicable

Actual start date of recruitment	02 July 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Poland: 23
Country: Number of subjects enrolled	Portugal: 6
Country: Number of subjects enrolled	Spain: 8
Country: Number of subjects enrolled	Czech Republic: 6
Country: Number of subjects enrolled	Germany: 2
Country: Number of subjects enrolled	Hungary: 14
Country: Number of subjects enrolled	Argentina: 18
Country: Number of subjects enrolled	Chile: 2
Country: Number of subjects enrolled	Korea, Republic of: 5
Country: Number of subjects enrolled	Mexico: 26
Country: Number of subjects enrolled	Peru: 6
Country: Number of subjects enrolled	Philippines: 13
Country: Number of subjects enrolled	Russian Federation: 28

Country: Number of subjects enrolled	Serbia: 63
Country: Number of subjects enrolled	Taiwan: 7
Country: Number of subjects enrolled	Ukraine: 33
Country: Number of subjects enrolled	United States: 52
Worldwide total number of subjects	312
EEA total number of subjects	59

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	312
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

A total of 312 subjects was randomized at 91 sites located in Europe (37 sites; 155 subjects), Asia-Pacific (19 sites, 53 subjects), North America (21 sites; 52 subjects), and Latin America (14 sites, 52 subjects). Consent was obtained from the first subject on 02 July 2015; the last subject completed the final visit on 25 January 2018.

Pre-assignment

Screening details:

Of the 568 subjects screened, 256 were screen failures and 312 were randomly assigned to treatment (modified Intent-to-treat [mITT] population). All subjects received study drug and were included in the safety population. Overall, 254 subjects were included in the Per Protocol (PP) population.

Period 1

Period 1 title	Overall Study Period (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

Blinding implementation details:

Study drug treatment allocation was double blind. As the highest dose of vobarilizumab (ALX-0061 225 mg q2w) exceeded the volume that could be administered in a single injection, subjects in the other 4 treatment groups were also administered 2 injections with 1 or both syringes containing placebo, depending on the assigned treatment group to maintain the blind. Blinding was maintained until the last subject enrolled completed the final evaluations and the database was locked.

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo

Arm description:

Two s.c. injections with placebo every 2 weeks (q2w)

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Placebo was supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes.
To maintain the blind, subjects randomly assigned to the placebo group received 2 s.c. injections q2w:
Syringe A with placebo (1 mL) q2w starting at Day 1, up to and including Week 46.
Syringe B with placebo (0.5 mL) q2w starting at Day 1, up to and including Week 46.

Arm title	ALX-0061 75 mg q4w

Arm description:

ALX-0061 75 mg every 4 weeks (q4w)

Arm type	Experimental
Investigational medicinal product name	ALX-0061
Investigational medicinal product code	
Other name	ALX-0061 Nanobody
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Vobarilizumab (ALX-0061) and placebo were supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes.
To maintain the blind, subjecs randomly assigned to ALX-0061 75 mg q4w received 2 s.c. injections q2w:
Syringe A with placebo (1 mL) q2w starting at Day 1, up to and including Week 46.
Syringe B with ALX-0061 (0.5 mL) q4w at Day 1, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44, and
syringe B with placebo (0.5 mL) q4w at Weeks 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, and 46.

Arm title	ALX-0061 150 mg q4w

Arm description:

ALX-0061 150 mg every 4 weeks (q4w)

Arm type	Experimental
Investigational medicinal product name	ALX-0061
Investigational medicinal product code	
Other name	ALX-0061 Nanobody
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Vobarilizumab (ALX-0061) and placebo were supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes.
To maintain the blind, subjecs randomly assigned to ALX-0061 150 mg q4w received 2 s.c. injections q2w:
Syringe A with ALX-0061 (1 mL) q4w at Day 1, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44, and syringe A with placebo (1 mL) q4w at Weeks 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, and 46.
Syringe B with placebo (0.5 mL) q2w starting at Day 1, up to and including Week 46.

Arm title	ALX-0061 150 mg q2w

Arm description:

ALX-0061 150 mg every 2 weeks (q2w)

Arm type	Experimental
Investigational medicinal product name	ALX-0061
Investigational medicinal product code	
Other name	ALX-0061 Nanobody
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Vobarilizumab (ALX-0061) and placebo were supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes.
To maintain the blind, subjecs randomly assigned to ALX-0061 150 mg q2w received 2 s.c. injections q2w:
Syringe A with ALX-0061 (1 mL) q2w starting at Day 1, up to and including Week 46.
Syringe B with placebo (0.5 mL) q2w starting at Day 1, up to and including Week 46.

Arm title	ALX-0061 225 mg q2w

Arm description:

ALX-0061 225 mg every 2 weeks (q2w)

Arm type	Experimental
Investigational medicinal product name	ALX-0061
Investigational medicinal product code	
Other name	ALX-0061 Nanobody
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Vobarilizumab (ALX-0061) was supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes.
To maintain the blind, subjecs randomly assigned to ALX-0061 225 mg q2w received 2 s.c. injections q2w:
Syringe A with ALX-0061 (1 mL) q2w starting at Day 1, up to and including Week 46.

Syringe B with ALX-0061 (0.5 mL) q2w starting at Day 1, up to and including Week 46.

Number of subjects in period 1	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w
Started	62	64	62
Completed	54	48	47
Not completed	8	16	15
Sponsor's decision	1	1	4
Adverse event, serious fatal	-	-	-
Consent withdrawn by subject	1	2	6
Physician decision	-	-	-
Adverse event, non-fatal	4	9	5
Other	1	-	-
Non-compliance to study drug	-	1	-
Lack of efficacy	1	3	-

Number of subjects in period 1	ALX-0061 150 mg q2w	ALX-0061 225 mg q2w
Started	62	62
Completed	40	46
Not completed	22	16
Sponsor's decision	-	2
Adverse event, serious fatal	2	-
Consent withdrawn by subject	5	5
Physician decision	1	-
Adverse event, non-fatal	11	7
Other	-	-
Non-compliance to study drug	-	1
Lack of efficacy	3	1

Baseline characteristics

Reporting groups	
Reporting group title	Placebo
Reporting group description:	
Two s.c. injections with placebo every 2 weeks (q2w)	
Reporting group title	ALX-0061 75 mg q4w
Reporting group description:	
ALX-0061 75 mg every 4 weeks (q4w)	
Reporting group title	ALX-0061 150 mg q4w
Reporting group description:	
ALX-0061 150 mg every 4 weeks (q4w)	
Reporting group title	ALX-0061 150 mg q2w
Reporting group description:	
ALX-0061 150 mg every 2 weeks (q2w)	
Reporting group title	ALX-0061 225 mg q2w
Reporting group description:	
ALX-0061 225 mg every 2 weeks (q2w)	

Reporting group values	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w
Number of subjects	62	64	62
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	62	64	62
From 65-84 years	0	0	0
85 years and over	0	0	0
Age continuous			
Units: years			
arithmetic mean	42.3	42.0	41.8
standard deviation	± 10.11	± 11.00	± 10.79
Gender categorical			
Units: Subjects			
Female	60	61	61
Male	2	3	1

Reporting group values	ALX-0061 150 mg q2w	ALX-0061 225 mg q2w	Total
Number of subjects	62	62	312
Age categorical			
Units: Subjects			
In utero	0	0	0

Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	62	62	312
From 65-84 years	0	0	0
85 years and over	0	0	0
Age continuous			
Units: years			
arithmetic mean	39.2	42.0	
standard deviation	± 11.58	± 10.44	-
Gender categorical			
Units: Subjects			
Female	61	57	300
Male	1	5	12

End points

End points reporting groups

Reporting group title	Placebo
Reporting group description: Two s.c. injections with placebo every 2 weeks (q2w)	
Reporting group title	ALX-0061 75 mg q4w
Reporting group description: ALX-0061 75 mg every 4 weeks (q4w)	
Reporting group title	ALX-0061 150 mg q4w
Reporting group description: ALX-0061 150 mg every 4 weeks (q4w)	
Reporting group title	ALX-0061 150 mg q2w
Reporting group description: ALX-0061 150 mg every 2 weeks (q2w)	
Reporting group title	ALX-0061 225 mg q2w
Reporting group description: ALX-0061 225 mg every 2 weeks (q2w)	

Primary: Percentage of subjects who achieved a response at Week 24 according to the modified British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (mBICLA) score

End point title	Percentage of subjects who achieved a response at Week 24 according to the modified British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (mBICLA) score

End point description:

The primary endpoint was evaluated by determining if there was a dose-response relationship between the mBICLA response rate at Week 24 and the dose administered, using the MCP-Mod methodology. The existence of several candidate parametric models was assumed and multiple comparison techniques were used to choose the model(s) most likely to represent the true underlying dose-response curve. The selected model could further be used to guide the choice of adequate doses.

mBICLA responders were defined as subjects who met all of the following criteria:
1. BILAG-2004 normal improvement: all A scores at Baseline improved to B, C or D, and all B scores improved to C or D.
2. No worsening in disease activity: no new BILAG-2004 A scores and ≤ 1 new increase to B.
3. No worsening of total mSLEDAI-2K score from Baseline.
4. No significant deterioration (< 10% worsening from Baseline) in PGA.
5. No treatment failure (including the premature discontinuation from study treatment).

End point type	Primary
End point timeframe: At Week 24 visit	

End point values	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w	ALX-0061 150 mg q2w
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62[1]	64[2]	62[3]	62[4]
Units: Percent responders	47	44	39	39

Notes:

[1] - mITT Population - Non-response imputation (NRI)

[2] - mITT Population - NRI

[3] - mITT Population - NRI

[4] - mITT Population - NRI

End point values	ALX-0061 225 mg q2w			
Subject group type	Reporting group			
Number of subjects analysed	62[5]			
Units: Percent responders	37			

Notes:

[5] - mITT Population - NRI

Statistical analyses

Statistical analysis title	Multiple Contrast Test - Linear model

Statistical analysis description:

A multiple contrast test was used to establish evidence of a drug effect by testing for a statistically significant dose-response signal for clinical endpoint and patient population investigated in the study. Candidate dose-response models were selected amongst the following types of parametric models: linear model, Emax model, logistic model, a 1st Beta model, and a 2nd Beta model.

Comparison groups	Placebo v ALX-0061 75 mg q4w v ALX-0061 150 mg q4w v ALX-0061 150 mg q2w v ALX-0061 225 mg q2w
Number of subjects included in analysis	312
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.526
Method	Multiple Contrast Test

Statistical analysis title	Multiple Contrast Test - Emax model

Statistical analysis description:

A multiple contrast test was used to establish evidence of a drug effect by testing for a statistically significant dose-response signal for clinical endpoint and patient population investigated in the study. Candidate dose-response models were selected amongst the following types of parametric models: linear model, Emax model, logistic model, a 1st Beta model, and a 2nd Beta model.

Comparison groups	Placebo v ALX-0061 75 mg q4w v ALX-0061 150 mg q4w v ALX-0061 150 mg q2w v ALX-0061 225 mg q2w
Number of subjects included in analysis	312
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.504
Method	Multiple Contrast Test

Statistical analysis title	Multiple Contrast Test - Logistic model

Statistical analysis description:

A multiple contrast test was used to establish evidence of a drug effect by testing for a statistically significant dose-response signal for clinical endpoint and patient population investigated in the study. Candidate dose-response models were selected amongst the following types of parametric models: linear model, Emax model, logistic model, a 1st Beta model, and a 2nd Beta model.

Comparison groups	Placebo v ALX-0061 75 mg q4w v ALX-0061 150 mg q4w v ALX-0061 150 mg q2w v ALX-0061 225 mg q2w
Number of subjects included in analysis	312
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.548
Method	Multiple Contrast Test

Statistical analysis title	Multiple Contrast Test - 1st Beta model

Statistical analysis description:

A multiple contrast test was used to establish evidence of a drug effect by testing for a statistically significant dose-response signal for clinical endpoint and patient population investigated in the study. Candidate dose-response models were selected amongst the following types of parametric models: linear model, Emax model, logistic model, a 1st Beta model, and a 2nd Beta model.

Comparison groups	Placebo v ALX-0061 75 mg q4w v ALX-0061 150 mg q4w v ALX-0061 150 mg q2w v ALX-0061 225 mg q2w
Number of subjects included in analysis	312
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.985
Method	Multiple Contrast Test

Statistical analysis title	Multiple Contrast Test - 2nd Beta model

Statistical analysis description:

A multiple contrast test was used to establish evidence of a drug effect by testing for a statistically significant dose-response signal for clinical endpoint and patient population investigated in the study. Candidate dose-response models were selected amongst the following types of parametric models: linear model, Emax model, logistic model, a 1st Beta model, and a 2nd Beta model.

Comparison groups	Placebo v ALX-0061 75 mg q4w v ALX-0061 150 mg q4w v ALX-0061 150 mg q2w v ALX-0061 225 mg q2w
Number of subjects included in analysis	312
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.524
Method	Multiple Contrast Test

Secondary: Proportion of subjects with mBICLA response at Week 24 and Week 48

End point title	Proportion of subjects with mBICLA response at Week 24 and Week 48

End point description:

Proportion of mBICLA responders at Week 24 and Week 48

End point type	Secondary

End point timeframe:

At Week 24 and Week 48

End point values	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w	ALX-0061 150 mg q2w
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62[6]	64[7]	62[8]	62[9]
Units: Percent responders				
Week 24	46	44	38	39
Week 48	48	53	37	32

Notes:

[6] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 61
Week 48: n = 59

[7] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 64
Week 48: n = 61

[8] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 58
Week 48: n = 60

[9] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 62
Week 48: n = 60

End point values	ALX-0061 225 mg q2w			
Subject group type	Reporting group			
Number of subjects analysed	62[10]			
Units: Percent responders				
Week 24	36			
Week 48	37			

Notes:

[10] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 61
Week 48: n = 60

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of subjects with modified Systemic Lupus Erythematosus Responder Index (mSRI-4) response at Week 24 and Week 48

End point title	Proportion of subjects with modified Systemic Lupus Erythematosus Responder Index (mSRI-4) response at Week 24 and Week 48

End point description:

Proportion of mSRI-4 responders at Week 24 and Week 48
Subjects who were treatment failures or discontinued from treatment were considered non-responder after treatment failure/discontinuation

End point type	Secondary

End point timeframe:

At Week 24 and Week 48

End point values	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w	ALX-0061 150 mg q2w
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62[11]	64[12]	62[13]	62[14]
Units: Percent responders				
Week 24	63	62	52	54
Week 48	59	60	49	45

Notes:

[11] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 59
Week 48: n = 58

[12] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 63
Week 48: n = 60

[13] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 58
Week 48: n = 59

[14] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 61
Week 48: n = 58

End point values	ALX-0061 225 mg q2w			
Subject group type	Reporting group			
Number of subjects analysed	62[15]			
Units: Percent responders				
Week 24	48			
Week 48	55			

Notes:

[15] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 60
Week 48: n = 60

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of subjects with mSRI-5 response at Week 24 and Week 48

End point title	Proportion of subjects with mSRI-5 response at Week 24 and Week 48

End point description:

Proportion of mSRI-5 responders at Week 24 and Week 48
Subjects who were treatment failures or discontinued from treatment were considered non-responder after treatment failure/discontinuation

End point type	Secondary

End point timeframe:

At Week 24 and Week 48

End point values	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w	ALX-0061 150 mg q2w
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62[16]	64[17]	62[18]	62[19]
Units: Percent responders				
Week 24	30	39	35	34
Week 48	36	48	33	29

Notes:

[16] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 57
Week 48: n = 56

[17] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 61
Week 48: n = 58

[18] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 54
Week 48: n = 55

[19] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 59
Week 48: n = 56

End point values	ALX-0061 225 mg q2w			
Subject group type	Reporting group			
Number of subjects analysed	62[20]			
Units: Percent responders				
Week 24	28			
Week 48	38			

Notes:

[20] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 58
Week 48: n = 58

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of subjects with mSRI-6 response at Week 24 and Week 48

End point title	Proportion of subjects with mSRI-6 response at Week 24 and Week 48

End point description:

Proportion of mSRI-6 responders at Week 24 and Week 48
Subjects who were treatment failures or discontinued from treatment were considered non-responder after treatment failure/discontinuation

End point type	Secondary

End point timeframe:

At Week 24 and Week 48

End point values	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w	ALX-0061 150 mg q2w
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62[21]	64[22]	62[23]	62[24]
Units: Percent responders				
Week 24	28	38	35	32
Week 48	36	48	29	29

Notes:

[21] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 57
Week 48: n = 56

[22] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 61
Week 48: n = 58

[23] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 54
Week 48: n = 55

[24] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 59
Week 48: n = 56

End point values	ALX-0061 225 mg q2w			
Subject group type	Reporting group			
Number of subjects analysed	62[25]			
Units: Percent responders				
Week 24	26			
Week 48	38			

Notes:

[25] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 58
Week 48: n = 58

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of subjects with mSRI-7 response at Week 24 and Week 48

End point title	Proportion of subjects with mSRI-7 response at Week 24 and Week 48

End point description:

Proportion of mSRI-7 responders at Week 24 and Week 48
Subjects who were treatment failures or discontinued from treatment were considered non-responder after treatment failure/discontinuation

End point type	Secondary

End point timeframe:

At Week 24 and Week 48

End point values	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w	ALX-0061 150 mg q2w
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62[26]	64[27]	62[28]	62[29]
Units: Percent responders				
Week 24	20	17	21	24
Week 48	26	31	18	17

Notes:

[26] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 46
Week 48: n = 46

[27] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 47
Week 48: n = 45

[28] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 39
Week 48: n = 40

[29] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 50
Week 48: n = 47

End point values	ALX-0061 225 mg q2w			
Subject group type	Reporting group			
Number of subjects analysed	62[30]			
Units: Percent responders				
Week 24	16			
Week 48	21			

Notes:

[30] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 43
Week 48: n = 42

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of subjects with mSRI-8 response at Week 24 and Week 48

End point title	Proportion of subjects with mSRI-8 response at Week 24 and Week 48

End point description:

Proportion of mSRI-8 responders at Week 24 and Week 48
Subjects who were treatment failures or discontinued from treatment were considered non-responder after treatment failure/discontinuation

End point type	Secondary

End point timeframe:

At Week 24 and Week 48

End point values	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w	ALX-0061 150 mg q2w
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62[31]	64[32]	62[33]	62[34]
Units: Percent responders				
Week 24	20	15	22	20
Week 48	24	31	18	15

Notes:

[31] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 45
Week 48: n = 45

[32] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 47
Week 48: n = 45

[33] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 37
Week 48: n = 38

[34] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 49
Week 48: n = 46

End point values	ALX-0061 225 mg q2w			
Subject group type	Reporting group			
Number of subjects analysed	62[35]			
Units: Percent responders				
Week 24	17			
Week 48	20			

Notes:

[35] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 42
Week 48: n = 41

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline in modified Systemic Lupus Erythematosus Disease Activity Index 2000 (mSLEDAI-2K) score at Week 24 and Week 48

End point title	Change from baseline in modified Systemic Lupus Erythematosus Disease Activity Index 2000 (mSLEDAI-2K) score at Week 24 and Week 48

End point description:

Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline mSLEDAI-2K Score and geographic region as covariates
A negative change from baseline reflects an improvement

End point type	Secondary

End point timeframe:

At Week 24 and Week 48

End point values	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w	ALX-0061 150 mg q2w
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62[36]	64[37]	62[38]	62[39]
Units: not applicable				
arithmetic mean (standard error)				
Week 24	-4.0 (± 0.42)	-4.6 (± 0.43)	-3.8 (± 0.43)	-4.3 (± 0.44)
Week 48	-4.5 (± 0.40)	-5.2 (± 0.43)	-4.3 (± 0.42)	-4.9 (± 0.48)

Notes:

[36] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 53
Week 48: n = 51

[37] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 50
Week 48: n = 46

[38] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 51
Week 48: n = 47

[39] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 48
Week 48: n = 36

End point values	ALX-0061 225 mg q2w			
Subject group type	Reporting group			
Number of subjects analysed	62[40]			
Units: not applicable				
arithmetic mean (standard error)				
Week 24	-3.6 (± 0.44)			
Week 48	-4.9 (± 0.44)			

Notes:

[40] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 51
Week 48: n = 45

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of subjects with BILAG-2004 Normal Improvement at Week 24 and Week 48

End point title	Proportion of subjects with BILAG-2004 Normal Improvement at Week 24 and Week 48

End point description:

Normal Improvement: all A scores at baseline improved to B/C/D, and all B scores improved to C or D
Only subjects with non-missing BILAG-2004 who had at least one A or B score at Baseline were assessed for this endpoint

End point type	Secondary

End point timeframe:

At Week 24 and Week 48

End point values	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w	ALX-0061 150 mg q2w
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62[41]	64[42]	62[43]	62[44]
Units: Percent responders				
Week 24	55	56	50	51
Week 48	63	71	58	56

Notes:

[41] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 56
Week 48: n = 54

[42] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 52
Week 48: n = 48

[43] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 56
Week 48: n = 50

[44] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 49
Week 48: n = 39

End point values	ALX-0061 225 mg q2w			
Subject group type	Reporting group			
Number of subjects analysed	62[45]			
Units: Percent responders				
Week 24	44			
Week 48	54			

Notes:

[45] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 54
Week 48: n = 46

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of subjects with BILAG-2004 Enhanced Improvement at Week 24 and Week 48

End point title	Proportion of subjects with BILAG-2004 Enhanced Improvement at Week 24 and Week 48

End point description:

Enhanced improvement: all A scores at baseline improved to B/C/D, and all B scores improved to C or D and no worsening between consecutive visits from baseline up to the considered visit
Only subjects with non-missing BILAG-2004 who had at least one A or B score at Baseline were assessed for this endpoint

End point type	Secondary

End point timeframe:

At Week 24 and Week 48

End point values	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w	ALX-0061 150 mg q2w
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62[46]	64[47]	62[48]	62[49]
Units: Percent responders				
Week 24	13	31	20	12
Week 48	9	21	14	15

Notes:

[46] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 56
Week 48: n = 54

[47] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 52
Week 48: n = 48

[48] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 56
Week 48: n = 50

[49] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 49
Week 48: n = 39

End point values	ALX-0061 225 mg q2w			
Subject group type	Reporting group			
Number of subjects analysed	62[50]			
Units: Percent responders				
Week 24	24			
Week 48	16			

Notes:

[50] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 54
Week 48: n = 45

Statistical analyses

No statistical analyses for this end point

Secondary: BILAG-2004 Total Score at Baseline, Week 24 and Week 48

End point title	BILAG-2004 Total Score at Baseline, Week 24 and Week 48

End point description:

End point type	Secondary

End point timeframe:

At Baseline, Week 24 and Week 48

End point values	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w	ALX-0061 150 mg q2w
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62[51]	64[52]	62[53]	62[54]
Units: not applicable				
arithmetic mean (standard error)				
Baseline	17.4 (± 0.78)	17.9 (± 0.69)	15.2 (± 0.68)	17.4 (± 0.71)
Week 24	6.8 (± 0.78)	5.7 (± 0.79)	7.0 (± 0.76)	7.2 (± 0.94)
Week 48	6.0 (± 0.73)	4.0 (± 0.72)	5.2 (± 0.74)	6.0 (± 0.92)

Notes:

[51] - mITT Population
Number of subjects at visit:
Baseline: n = 62
Week 24: n = 56
Week 48: n = 53

[52] - mITT Population
Number of subjects at visit:
Baseline: n = 64
Week 24: n = 52
Week 48: n = 48

[53] - mITT Population
Number of subjects at visit:
Baseline: n = 62
Week 24: n = 56
Week 48: n = 50

[54] - mITT Population
Number of subjects at visit:
Baseline: n = 62
Week 24: n = 49
Week 48: n = 39

End point values	ALX-0061 225 mg q2w			
Subject group type	Reporting group			
Number of subjects analysed	62[55]			
Units: not applicable				
arithmetic mean (standard error)				
Baseline	17.3 (± 0.82)			
Week 24	7.4 (± 0.84)			
Week 48	6.2 (± 0.91)			

Notes:

[55] - mITT Population
Number of subjects at visit:
Baseline: n = 62
Week 24: n = 54
Week 48: n = 45

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of subjects with BILAG-2004 Normal Improvement in mucocutaneous system at Week 24 and Week 48

End point title	Proportion of subjects with BILAG-2004 Normal Improvement in mucocutaneous system at Week 24 and Week 48

End point description:

An improvement is defined as an A score at Baseline improved to B/C/D, or a B score improved to C or D.
Only subjects with non-missing BILAG-2004 who had at least one A or B score at Baseline were assessed for this endpoint

End point type	Secondary

End point timeframe:

At Week 24 and Week 48

End point values	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w	ALX-0061 150 mg q2w
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62[56]	64[57]	62[58]	62[59]
Units: Percent responders				
Week 24	53	53	42	49
Week 48	58	66	49	53

Notes:

[56] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 47
Week 48: n = 45

[57] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 45
Week 48: n = 41

[58] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 43
Week 48: n = 37

[59] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 43
Week 48: n = 34

End point values	ALX-0061 225 mg q2w			
Subject group type	Reporting group			
Number of subjects analysed	62[60]			
Units: Percent responders				
Week 24	53			
Week 48	55			

Notes:

[60] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 47
Week 48: n = 40

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of subjects with BILAG-2004 Normal Improvement in musculoskeletal system at Week 24 and Week 48

End point title	Proportion of subjects with BILAG-2004 Normal Improvement in musculoskeletal system at Week 24 and Week 48

End point description:

An improvement is defined as an A score at Baseline improved to B/C/D, or a B score improved to C or D.
Only subjects with non-missing BILAG-2004 who had at least one A or B score at Baseline were assessed for this endpoint

End point type	Secondary

End point timeframe:

At Week 24 and Week 48

End point values	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w	ALX-0061 150 mg q2w
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62[61]	64[62]	62[63]	62[64]
Units: Percent responders				
Week 24	87	89	84	80
Week 48	89	95	88	89

Notes:

[61] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 47
Week 48: n = 45

[62] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 44
Week 48: n = 40

[63] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 43
Week 48: n = 40

[64] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 45
Week 48: n = 37

End point values	ALX-0061 225 mg q2w			
Subject group type	Reporting group			
Number of subjects analysed	62[65]			
Units: Percent responders				
Week 24	73			
Week 48	82			

Notes:

[65] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 45
Week 48: n = 38

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of subjects with persistent minimal or no activity in 9 organ systems according to BILAG-2004 Systems Tally at Week 24 and Week 48

End point title	Proportion of subjects with persistent minimal or no activity in 9 organ systems according to BILAG-2004 Systems Tally at Week 24 and Week 48

End point description:

End point type	Secondary

End point timeframe:

At Week 24 and Week 48

End point values	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w	ALX-0061 150 mg q2w
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62[66]	64[67]	62[68]	62[69]
Units: Percent responders				
Week 24	27	46	34	33
Week 48	37	56	46	41

Notes:

[66] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 56
Week 48: n = 54

[67] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 52
Week 48: n = 48

[68] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 56
Week 48: n = 50

[69] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 49
Week 48: n = 39

End point values	ALX-0061 225 mg q2w			
Subject group type	Reporting group			
Number of subjects analysed	62[70]			
Units: Percent responders				
Week 24	30			
Week 48	41			

Notes:

[70] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 54
Week 48: n = 46

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline in Physician's Global Assessment (PGA) at Week 24 and Week 48

End point title	Change from baseline in Physician's Global Assessment (PGA) at Week 24 and Week 48

End point description:

Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline PGA Score and geographic region as covariates.
A negative change from baseline reflects an improvement.

End point type	Secondary

End point timeframe:

At Week 24 and Week 48

End point values	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w	ALX-0061 150 mg q2w
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62[71]	64[72]	62[73]	62[74]
Units: not applicable				
arithmetic mean (standard error)				
Week 24	-25.2 (± 2.03)	-28.4 (± 2.09)	-26.2 (± 2.04)	-23.5 (± 2.16)
Week 48	-28.3 (± 1.73)	-32.9 (± 1.82)	-30.2 (± 1.82)	-30.1 (± 2.00)

Notes:

[71] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 56
Week 48: n = 54

[72] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 52
Week 48: n = 48

[73] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 55
Week 48: n = 48

[74] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 49
Week 48: n = 39

End point values	ALX-0061 225 mg q2w			
Subject group type	Reporting group			
Number of subjects analysed	62[75]			
Units: not applicable				
arithmetic mean (standard error)				
Week 24	-22.7 (± 2.08)			
Week 48	-30.5 (± 1.87)			

Notes:

[75] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 54
Week 48: n = 46

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline in Patient's Global Assessment at Week 24 and Week 48

End point title	Change from baseline in Patient's Global Assessment at Week 24 and Week 48

End point description:

Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline Patient's Global Assessment and geographic region as covariates.
A negative change from baseline reflects an improvement.

End point type	Secondary

End point timeframe:

At Week 24 and Week 48

End point values	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w	ALX-0061 150 mg q2w
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62[76]	64[77]	62[78]	62[79]
Units: not applicable				
arithmetic mean (standard error)				
Week 24	-12.4 (± 2.87)	-13.5 (± 2.96)	-14.9 (± 2.87)	-20.1 (± 3.05)
Week 48	-15.1 (± 2.70)	-21.5 (± 2.87)	-22.1 (± 2.82)	-27.2 (± 3.12)

Notes:

[76] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 56
Week 48: n = 54

[77] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 52
Week 48: n = 48

[78] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 56
Week 48: n = 49

[79] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 49
Week 48: n = 39

End point values	ALX-0061 225 mg q2w			
Subject group type	Reporting group			
Number of subjects analysed	62[80]			
Units: not applicable				
arithmetic mean (standard error)				
Week 24	-16.0 (± 2.98)			
Week 48	-25.9 (± 2.94)			

Notes:

[80] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 53
Week 48: n = 46

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline in proteinuria at Week 24 and Week 48

End point title	Change from baseline in proteinuria at Week 24 and Week 48

End point description:

Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline proteinuria and geographic region as covariates

End point type	Secondary

End point timeframe:

At Week 24 and Week 48

End point values	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w	ALX-0061 150 mg q2w
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62[81]	64[82]	62[83]	62[84]
Units: g/mol				
arithmetic mean (standard error)				
Week 24	6.17 (± 3.730)	1.77 (± 3.847)	1.03 (± 3.735)	-3.02 (± 3.876)
Week 48	4.89 (± 5.732)	3.83 (± 6.152)	-1.62 (± 5.761)	-0.49 (± 6.582)

Notes:

[81] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 48
Week 48: n = 43
[82] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 44
Week 48: n = 37
[83] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 48
Week 48: n = 42
[84] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 42
Week 48: n = 30

End point values	ALX-0061 225 mg q2w			
Subject group type	Reporting group			
Number of subjects analysed	62[85]			
Units: g/mol				
arithmetic mean (standard error)				
Week 24	0.16 (± 3.962)			
Week 48	-1.21 (± 6.191)			

Notes:

[85] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 42
Week 48: n = 36

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects who were treatment-emergent urine sediment positive at Week 24 and Week 48

End point title	Number of subjects who were treatment-emergent urine sediment positive at Week 24 and Week 48

End point description:

Efficacy Laboratory Parameters (Urinalysis) - Active Urine Sediment
Number of subjects who were urine sediment negative at Baseline, but positive at Week 24 and Week 48, respectively

End point type	Secondary

End point timeframe:

At Week 24 and Week 48

End point values	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w	ALX-0061 150 mg q2w
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62[86]	64[87]	62[88]	62[89]
Units: Number of subjects				
Week 24	1	0	0	0
Week 48	0	0	0	0

Notes:

[86] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 56
Week 48: n = 54

[87] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 52
Week 48: n = 48

[88] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 56
Week 48: n = 50

[89] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 49
Week 48: n = 39

End point values	ALX-0061 225 mg q2w			
Subject group type	Reporting group			
Number of subjects analysed	62[90]			
Units: Number of subjects				
Week 24	0			
Week 48	0			

Notes:

[90] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 54
Week 48: n = 46

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline in serum creatinine at Week 24 and Week 48

End point title	Change from baseline in serum creatinine at Week 24 and Week 48

End point description:

Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline serum creatinine and geographic region as covariates

End point type	Secondary

End point timeframe:

At Week 24 and Week 48

End point values	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w	ALX-0061 150 mg q2w
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62[91]	64[92]	62[93]	62[94]
Units: umol/L				
arithmetic mean (standard error)				
Week 24	-1.25 (± 2.172)	-3.29 (± 2.237)	-1.50 (± 2.182)	-3.98 (± 2.309)
Week 48	1.19 (± 2.016)	-1.87 (± 2.152)	-6.26 (± 2.085)	-4.04 (± 2.359)

Notes:

[91] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 56
Week 48: n = 54
[92] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 52
Week 48: n = 47
[93] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 56
Week 48: n = 50
[94] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 49
Week 48: n = 38

End point values	ALX-0061 225 mg q2w			
Subject group type	Reporting group			
Number of subjects analysed	62[95]			
Units: umol/L				
arithmetic mean (standard error)				
Week 24	-0.86 (± 2.276)			
Week 48	-1.24 (± 2.199)			

Notes:

[95] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 53
Week 48: n = 46

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline in Creatinine Clearance Estimation (eGFR) at Week 24 and Week 48

End point title	Change from baseline in Creatinine Clearance Estimation (eGFR) at Week 24 and Week 48

End point description:

Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline eGFR and geographic region as covariates

End point type	Secondary

End point timeframe:

At Week 24 and Week 48

End point values	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w	ALX-0061 150 mg q2w
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62[96]	64[97]	62[98]	62[99]
Units: mL/min/1.73m2				
arithmetic mean (standard error)				
Week 24	-1.63 (± 2.869)	4.83 (± 2.931)	-1.72 (± 2.854)	-0.90 (± 3.044)
Week 48	-6.00 (± 3.052)	2.47 (± 3.231)	4.66 (± 3.125)	-1.47 (± 3.562)

Notes:

[96] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 55
Week 48: n = 53

[97] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 52
Week 48: n = 47

[98] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 56
Week 48: n = 50

[99] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 49
Week 48: n = 38

End point values	ALX-0061 225 mg q2w			
Subject group type	Reporting group			
Number of subjects analysed	62[100]			
Units: mL/min/1.73m2				
arithmetic mean (standard error)				
Week 24	-8.91 (± 3.014)			
Week 48	-8.08 (± 3.326)			

Notes:

[100] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 53
Week 48: n = 46

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage treatment failures from Baseline to Week 24 and Week 48

End point title	Percentage treatment failures from Baseline to Week 24 and Week 48

End point description:

Defined as non-protocol allowed increase in steroid dose, start i.v. or i.m. steroids, or start or increase of immunosuppressant

End point type	Secondary

End point timeframe:

From Baseline to Week 24 and Week 48

End point values	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w	ALX-0061 150 mg q2w
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62[101]	64[102]	62[103]	62[104]
Units: Percent treatment failures				
Baseline to Week 24	3	0	7	3
Baseline to Week 48	8	2	15	10

Notes:

[101] - mITT Population

[102] - mITT Population

[103] - mITT Population

[104] - mITT Population

End point values	ALX-0061 225 mg q2w			
Subject group type	Reporting group			
Number of subjects analysed	62[105]			
Units: Percent treatment failures				
Baseline to Week 24	5			
Baseline to Week 48	10			

Notes:

[105] - mITT Population

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of subjects experiencing severe flares according to BILAG-2004 Flare Index from Baseline to Week 24 and Week 48

End point title	Proportion of subjects experiencing severe flares according to BILAG-2004 Flare Index from Baseline to Week 24 and Week 48

End point description:

End point type	Secondary

End point timeframe:

From Baseline to Week 24 and Week 48

End point values	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w	ALX-0061 150 mg q2w
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62[106]	64[107]	62[108]	62[109]
Units: Percent				
Baseline to Week 24	13	9	10	11
Baseline to Week 48	13	9	16	15

Notes:

[106] - mITT Population

[107] - mITT Population

[108] - mITT Population

[109] - mITT Population

End point values	ALX-0061 225 mg q2w			
Subject group type	Reporting group			
Number of subjects analysed	62[110]			
Units: Percent				
Baseline to Week 24	10			
Baseline to Week 48	15			

Notes:

[110] - mITT Population

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of subjects experiencing severe flares according to mSLEDAI-2K Flare Index (mSFI) from Baseline to Week 24 and Week 48

End point title	Proportion of subjects experiencing severe flares according to mSLEDAI-2K Flare Index (mSFI) from Baseline to Week 24 and Week 48

End point description:

End point type	Secondary

End point timeframe:

From baseline to Week 24 and Week 48

End point values	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w	ALX-0061 150 mg q2w
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62[111]	64[112]	62[113]	62[114]
Units: Percent				
Baseline to Week 24	2	0	3	3
Baseline to Week 48	6	0	6	6

Notes:

[111] - mITT Population

[112] - mITT Population

[113] - mITT Population

[114] - mITT Population

End point values	ALX-0061 225 mg q2w			
Subject group type	Reporting group			
Number of subjects analysed	62[115]			
Units: Percent				
Baseline to Week 24	2			
Baseline to Week 48	3			

Notes:

[115] - mITT Population

Statistical analyses

No statistical analyses for this end point

Secondary: Percent change from baseline in daily dose of steroids at Week 24 and Week 48

End point title	Percent change from baseline in daily dose of steroids at Week 24 and Week 48

End point description:

Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline prednisone equivalent total daily dose and geographic region as covariates

End point type	Secondary

End point timeframe:

At Week 24 and Week 48

End point values	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w	ALX-0061 150 mg q2w
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62[116]	64[117]	62[118]	62[119]
Units: percent				
arithmetic mean (standard error)				
Week 24	3.87 (± 2.781)	-0.80 (± 2.922)	0.25 (± 2.689)	-1.40 (± 2.940)
Week 48	6.93 (± 5.047)	-3.22 (± 5.397)	-1.03 (± 5.050)	-2.32 (± 5.758)

Notes:

[116] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 48
Week 48: n = 46

[117] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 43
Week 48: n = 40

[118] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 51
Week 48: n = 45

[119] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 43
Week 48: n = 34

End point values	ALX-0061 225 mg q2w			
Subject group type	Reporting group			
Number of subjects analysed	62[120]			
Units: percent				
arithmetic mean (standard error)				
Week 24	-3.46 (± 2.831)			
Week 48	-1.73 (± 5.521)			

Notes:

[120] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 48
Week 48: n = 40

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of subjects whose daily dose of steroids was reduced without severe flares during Weeks 40-48

End point title	Proportion of subjects whose daily dose of steroids was reduced without severe flares during Weeks 40-48

End point description:

Proportion of subjects whose prednisone equivalent dose was >7.5 mg/day at baseline and reduced to ≤7.5 mg/day during Weeks 40-48 without experiencing a BILAG-2004-defined or mSFI-defined severe flare after the first prednisone equivalent dose decrease.

End point type	Secondary

End point timeframe:

Between Week 40 and Week 48

End point values	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w	ALX-0061 150 mg q2w
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	34[121]	36[122]	30[123]	32[124]
Units: Percent				
BILAG-2004-defined Flare	9	6	17	3
mSFI-defined Flare	9	6	13	3

Notes:

[121] - mITT Population

[122] - mITT Population

[123] - mITT Population

[124] - mITT Population

End point values	ALX-0061 225 mg q2w			
Subject group type	Reporting group			
Number of subjects analysed	36[125]			

Units: Percent				
BILAG-2004-defined Flare	8			
mSFI-defined Flare	11			

Notes:

[125] - mITT Population

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of subjects who discontinued Prednisone (or equivalent) by Week 48 without experiencing a severe flare

End point title	Proportion of subjects who discontinued Prednisone (or equivalent) by Week 48 without experiencing a severe flare

End point description:

Proportion of subjects who discontinued Prednisone (or equivalent) by Week 48 without experiencing a BILAG-2004-defined or mSFI-defined severe flare

End point type	Secondary

End point timeframe:

Up to and including Week 48

End point values	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w	ALX-0061 150 mg q2w
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	54[126]	52[127]	55[128]	54[129]
Units: Percent				
BILAG-2004-defined flare	0	0	2	2
mSFI-defined flare	0	0	4	2

Notes:

[126] - mITT Population

[127] - mITT Population

[128] - mITT Population

[129] - mITT Population

End point values	ALX-0061 225 mg q2w			
Subject group type	Reporting group			
Number of subjects analysed	56[130]			
Units: Percent				
BILAG-2004-defined flare	0			
mSFI-defined flare	0			

Notes:

[130] - mITT Population

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline in physical component scores of Short Form (36)

Health Survey (SF-36) at Week 24 and Week 48

End point title	Change from baseline in physical component scores of Short Form (36) Health Survey (SF-36) at Week 24 and Week 48

End point description:

Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline SF-36 Score and geographic region as covariates.
A positive change denotes an improvement.

End point type	Secondary

End point timeframe:

At Week 24 and Week 48

End point values	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w	ALX-0061 150 mg q2w
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62[131]	64[132]	62[133]	62[134]
Units: not applicable				
arithmetic mean (standard error)				
Week 24	4.71 (± 1.241)	4.56 (± 1.286)	6.77 (± 1.242)	4.67 (± 1.321)
Week 48	3.73 (± 1.414)	6.97 (± 1.510)	8.67 (± 1.460)	8.62 (± 1.633)

Notes:

[131] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 56
Week 48: n = 54

[132] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 52
Week 48: n = 48

[133] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 56
Week 48: n = 50

[134] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 49
Week 48: n = 39

End point values	ALX-0061 225 mg q2w			
Subject group type	Reporting group			
Number of subjects analysed	62[135]			
Units: not applicable				
arithmetic mean (standard error)				
Week 24	5.01 (± 1.292)			
Week 48	8.85 (± 1.535)			

Notes:

[135] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 53
Week 48: n = 46

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline in mental component scores of SF-36 at Week 24 and Week 48

End point title	Change from baseline in mental component scores of SF-36 at Week 24 and Week 48

End point description:

Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline SF-36 Score and geographic region as covariates.
A positive change denotes an improvement.

End point type	Secondary

End point timeframe:

At Week 24 and Week 48

End point values	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w	ALX-0061 150 mg q2w
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62[136]	64[137]	62[138]	62[139]
Units: not applicable				
arithmetic mean (standard error)				
Week 24	0.08 (± 0.703)	-0.99 (± 0.724)	-0.56 (± 0.703)	0.45 (± 0.749)
Week 48	1.50 (± 0.716)	-0.58 (± 0.756)	-0.07 (± 0.737)	-1.07 (± 0.827)

Notes:

[136] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 56
Week 48: n = 54

[137] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 52
Week 48: n = 48

[138] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 56
Week 48: n = 50

[139] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 49
Week 48: n = 39

End point values	ALX-0061 225 mg q2w			
Subject group type	Reporting group			
Number of subjects analysed	62[140]			
Units: not applicable				
arithmetic mean (standard error)				
Week 24	-1.18 (± 0.732)			
Week 48	-2.02 (± 0.777)			

Notes:

[140] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 53
Week 48: n = 46

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline in 28 joint count swollenness (SJC28) score at Week 24 and Week 48

End point title	Change from baseline in 28 joint count swollenness (SJC28) score at Week 24 and Week 48

End point description:

Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline SJC28 Score and geographic region as covariates
A negative change denotes an improvement

End point type	Secondary

End point timeframe:

At Week 24 and Week 48

End point values	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w	ALX-0061 150 mg q2w
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62[141]	64[142]	62[143]	62[144]
Units: not applicable				
arithmetic mean (standard error)				
Week 24	-4.8 (± 0.31)	-5.0 (± 0.32)	-4.9 (± 0.31)	-4.8 (± 0.33)
Week 48	-5.0 (± 0.28)	-5.4 (± 0.30)	-4.7 (± 0.29)	-5.1 (± 0.32)

Notes:

[141] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 56
Week 48: n = 54

[142] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 52
Week 48: n = 48

[143] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 56
Week 48: n = 50

[144] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 49
Week 48: n = 39

End point values	ALX-0061 225 mg q2w			
Subject group type	Reporting group			
Number of subjects analysed	62[145]			
Units: not applicable				
arithmetic mean (standard error)				
Week 24	-4.5 (± 0.32)			
Week 48	-4.5 (± 0.30)			

Notes:

[145] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 54
Week 48: n = 46

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline in 28 joint count tenderness (TJC28) score at Week 24 and Week 48

End point title	Change from baseline in 28 joint count tenderness (TJC28) score at Week 24 and Week 48

End point description:

Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline TJC28 Score and geographic region as covariates
A negative change denotes and improvement

End point type	Secondary

End point timeframe:

At Week 24 and Week 48

End point values	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w	ALX-0061 150 mg q2w
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62[146]	64[147]	62[148]	62[149]
Units: not applicable				
arithmetic mean (standard error)				
Week 24	-6.8 (± 0.49)	-6.8 (± 0.50)	-6.4 (± 0.49)	-5.8 (± 0.52)
Week 48	-6.6 (± 0.43)	-7.4 (± 0.46)	-6.4 (± 0.45)	-6.6 (± 0.50)

Notes:

[146] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 56
Week 48: n = 54

[147] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 52
Week 48: n = 48

[148] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 56
Week 48: n = 50

[149] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 49
Week 48: n = 39

End point values	ALX-0061 225 mg q2w			
Subject group type	Reporting group			
Number of subjects analysed	62[150]			
Units: not applicable				
arithmetic mean (standard error)				
Week 24	-5.5 (± 0.50)			
Week 48	-6.5 (± 0.47)			

Notes:

[150] - mITT Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 54
Week 48: n = 46

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score at Week 12, Week 24 and Week 48

End point title	Change from baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score at Week 12, Week 24 and Week 48

End point description:

Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline CLASI Activity Score and geographic region as covariates.
A negative change denotes an improvement.

End point type	Secondary

End point timeframe:

At Week 12, Week 24 and Week 48

End point values	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w	ALX-0061 150 mg q2w
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62[151]	64[152]	62[153]	62[154]
Units: not applicable				
arithmetic mean (standard error)				
Week 12	-2.4 (± 0.53)	-1.9 (± 0.57)	-1.4 (± 0.65)	-1.6 (± 0.63)
Week 24	-1.1 (± 0.53)	-2.1 (± 0.60)	-1.6 (± 0.66)	-1.3 (± 0.65)
Week 48	-1.3 (± 0.59)	-3.0 (± 0.70)	-2.5 (± 0.73)	-2.1 (± 0.80)

Notes:

[151] - mITT Population
Number of subjects at visit:
Week 12: n = 26
Week 24: n = 25
Week 48: n = 24

[152] - mITT Population
Number of subjects at visit:
Week 12: n = 25
Week 24: n = 21
Week 48: n = 18

[153] - mITT Population
Number of subjects at visit:
Week 12: n = 18
Week 24: n = 17
Week 48: n = 16

[154] - mITT Population
Number of subjects at visit:
Week 12: n = 21
Week 24: n = 19
Week 48: n = 14

End point values	ALX-0061 225 mg q2w			
Subject group type	Reporting group			
Number of subjects analysed	62[155]			
Units: not applicable				
arithmetic mean (standard error)				
Week 12	-1.3 (± 0.57)			
Week 24	-1.8 (± 0.57)			

Week 48	-3.0 (± 0.64)			

Notes:

[155] - mITT Population
Number of subjects at visit:
Week 12: n = 24
Week 24: n = 23
Week 48: n = 21

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline in CLASI Damage Score at Week 12, Week 24 and Week 48

End point title	Change from baseline in CLASI Damage Score at Week 12, Week 24 and Week 48

End point description:

Mean changes from baseline were derived from an analysis of covariance (ANCOVA) model with treatment as factor and baseline CLASI Damage Score and geographic region as covariates
A negative change denotes an improvement

End point type	Secondary

End point timeframe:

At Week 12, Week 24 and Week 48

End point values	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w	ALX-0061 150 mg q2w
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62[156]	64[157]	62[158]	62[159]
Units: not applicable				
arithmetic mean (standard error)				
Week 12	0.1 (± 0.49)	0.1 (± 0.47)	-0.1 (± 0.59)	-0.3 (± 0.52)
Week 24	0.4 (± 0.61)	-0.4 (± 0.61)	-0.4 (± 0.73)	0.3 (± 0.67)
Week 48	0.0 (± 0.57)	-0.1 (± 0.60)	-0.3 (± 0.68)	0.4 (± 0.68)

Notes:

[156] - mITT Population
Number of subjects at visit:
Week 12: n = 11
Week 24: n = 11
Week 48: n = 11

[157] - mITT Population
Number of subjects at visit:
Week 12: n = 14
Week 24: n = 11
Week 48: n = 9

[158] - mITT Population
Number of subjects at visit:
Week 12: n = 8
Week 24: n = 8
Week 48: n = 8

[159] - mITT Population
Number of subjects at visit:
Week 12: n = 13
Week 24: n = 11
Week 48: n = 8

End point values	ALX-0061 225 mg q2w			

Subject group type	Reporting group			
Number of subjects analysed	62[160]			
Units: not applicable				
arithmetic mean (standard error)				
Week 12	-0.4 (± 0.52)			
Week 24	-0.1 (± 0.66)			
Week 48	-0.7 (± 0.63)			

Notes:

[160] - mITT Population
Number of subjects at visit:
Week 12: n = 13
Week 24: n = 12
Week 48: n = 11

Statistical analyses

No statistical analyses for this end point

Secondary: ALX-0061 Serum Concentrations at Week 24 and Week 48

End point title	ALX-0061 Serum Concentrations at Week 24 and Week 48[161]

End point description:

End point type	Secondary

End point timeframe:

At Week 24 and Week 48

Notes:

[161] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: PK was only measured in active treatment groups.

End point values	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w	ALX-0061 150 mg q2w	ALX-0061 225 mg q2w
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	64[162]	62[163]	62[164]	62[165]
Units: µg/mL				
geometric mean (geometric coefficient of variation)				
Week 24	0.118 (± 2.29)	2.05 (± 3.89)	18.1 (± 1.60)	30.7 (± 1.62)
Week 48	0.155 (± 3.28)	2.17 (± 3.45)	17.9 (± 1.71)	36.1 (± 1.46)

Notes:

[162] - Safety Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 43
Week 48: n = 33
[163] - Safety Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 53
Week 48: n = 43
[164] - Safety Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 47
Week 48: n = 32
[165] - Safety Population
Number of subjects (n) evaluated at the visit:
Week 24: n = 50
Week 48: n = 42

Statistical analyses

No statistical analyses for this end point

Secondary: Actual values of soluble Interleukin 6 Receptor (sIL-6R) concentrations at Baseline, Week 24, and Week 48

End point title	Actual values of soluble Interleukin 6 Receptor (sIL-6R) concentrations at Baseline, Week 24, and Week 48

End point description:

End point type	Secondary

End point timeframe:

At Baseline, Week 24, and Week 48

End point values	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w	ALX-0061 150 mg q2w
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62[166]	64[167]	62[168]	62[169]
Units: ng/mL				
arithmetic mean (standard error)				
Baseline	42.22 (± 2.496)	37.63 (± 1.933)	38.10 (± 1.895)	42.14 (± 3.366)
Week 24	39.70 (± 1.934)	198.26 (± 18.856)	603.51 (± 31.678)	668.57 (± 25.568)
Week 48	39.41 (± 2.270)	224.66 (± 25.515)	610.86 (± 29.445)	650.73 (± 38.516)

Notes:

[166] - Safety Population
Number of subjects at visit:
Baseline: n = 62
Week 24: n = 55
Week 48: n = 53

[167] - Safety Population
Number of subjects at visit:
Baseline: n = 63
Week 24: n = 51
Week 48: n = 47

[168] - Safety Population
Number of subjects at visit:
Baseline: n = 62
Week 24: n = 54
Week 48: n = 50

[169] - Safety Population
Number of subjects at visit:
Baseline: n = 62
Week 24: n = 49
Week 48: n = 38

End point values	ALX-0061 225 mg q2w			
Subject group type	Reporting group			
Number of subjects analysed	62[170]			
Units: ng/mL				
arithmetic mean (standard error)				
Baseline	36.92 (± 1.810)			

Week 24	634.49 (± 23.638)			
Week 48	659.79 (± 32.862)			

Notes:

[170] - Safety Population
Number of subjects at visit:
Baseline: n = 60
Week 24: n = 53
Week 48: n = 46

Statistical analyses

No statistical analyses for this end point

Secondary: Actual values of C-reactive protein (CRP) concentrations at Baseline, Week 24, and Week 48

End point title	Actual values of C-reactive protein (CRP) concentrations at Baseline, Week 24, and Week 48

End point description:

End point type	Secondary

End point timeframe:

At Baseline, Week 24, and Week 48

End point values	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w	ALX-0061 150 mg q2w
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62[171]	64[172]	62[173]	62[174]
Units: nmol/L				
arithmetic mean (standard error)				
Baseline	43.58 (± 9.527)	49.05 (± 12.924)	38.89 (± 8.394)	66.32 (± 17.221)
Week 24	59.43 (± 11.277)	47.22 (± 9.607)	26.08 (± 9.995)	3.83 (± 0.668)
Week 48	30.70 (± 4.709)	37.65 (± 8.647)	23.20 (± 6.705)	4.41 (± 0.988)

Notes:

[171] - Safety Population
Number of subjects at visit:
Baseline: n = 62
Week 24: n = 56
Week 48: n = 54

[172] - Safety Population
Number of subjects at visit:
Baseline: n = 64
Week 24: n = 52
Week 48: n = 46

[173] - Safety Population
Number of subjects at visit:
Baseline: n = 62
Week 24: n = 56
Week 48: n = 50

[174] - Safety Population
Number of subjects at visit:
Baseline: n = 62
Week 24: n = 49

Week 48: n = 38

End point values	ALX-0061 225 mg q2w			
Subject group type	Reporting group			
Number of subjects analysed	62[175]			
Units: nmol/L				
arithmetic mean (standard error)				
Baseline	32.23 (± 4.957)			
Week 24	3.20 (± 0.357)			
Week 48	4.02 (± 0.962)			

Notes:

[175] - Safety Population
Number of subjects at visit:
Baseline: n = 62
Week 24: n = 53
Week 48: n = 46

Statistical analyses

No statistical analyses for this end point

Secondary: Actual values of fibrinogen concentrations at Baseline, Week 24, and Week 48

End point title	Actual values of fibrinogen concentrations at Baseline, Week 24, and Week 48

End point description:

End point type	Secondary

End point timeframe:

At Baseline, Week 24, and Week 48

End point values	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w	ALX-0061 150 mg q2w
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62[176]	64[177]	62[178]	62[179]
Units: g/L				
arithmetic mean (standard error)				
Baseline	3.2 (± 0.09)	3.2 (± 0.08)	3.2 (± 0.09)	3.2 (± 0.10)
Week 24	3.3 (± 0.08)	3.3 (± 0.10)	2.3 (± 0.12)	1.9 (± 0.05)
Week 48	3.3 (± 0.09)	3.3 (± 0.12)	2.3 (± 0.11)	1.9 (± 0.06)

Notes:

[176] - Safety Population
Number of subjects at visit:
Baseline: n = 62
Week 24: n = 55
Week 48: n = 51
[177] - Safety Population
Number of subjects at visit:
Baseline: n = 64

Week 24: n = 52
Week 48: n = 48
[178] - Safety Population
Number of subjects at visit:
Baseline: n = 62
Week 24: n = 54
Week 48: n = 49
[179] - Safety Population
Number of subjects at visit:
Baseline: n = 62
Week 24: n = 49
Week 48: n = 36

End point values	ALX-0061 225 mg q2w			
Subject group type	Reporting group			
Number of subjects analysed	62[180]			
Units: g/L				
arithmetic mean (standard error)				
Baseline	3.1 (± 0.09)			
Week 24	1.9 (± 0.05)			
Week 48	1.9 (± 0.05)			

Notes:
[180] - Safety Population
Number of subjects at visit:
Baseline: n = 62
Week 24: n = 51
Week 48: n = 46

Statistical analyses

No statistical analyses for this end point

Secondary: Actual values of anti-double-stranded (ds) DNA concentrations at Baseline, Week 24, and Week 48

End point title	Actual values of anti-double-stranded (ds) DNA concentrations at Baseline, Week 24, and Week 48

End point description:

End point type	Secondary

End point timeframe:
At Baseline, Week 24, and Week 48

End point values	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w	ALX-0061 150 mg q2w
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62[181]	64[182]	62[183]	62[184]
Units: IU/mL				
arithmetic mean (standard error)				
Baseline	132.90 (± 54.467)	145.87 (± 113.907)	52.88 (± 17.283)	68.92 (± 23.226)
Week 24	81.36 (± 30.376)	68.27 (± 35.053)	46.99 (± 33.534)	14.98 (± 4.499)
Week 48	81.80 (± 24.143)	59.48 (± 32.190)	74.21 (± 48.030)	9.13 (± 2.108)

Notes:

[181] - Safety Population
Number of subjects at visit:
Baseline: n = 62
Week 24: n = 55
Week 48: n = 54

[182] - Safety Population
Number of subjects at visit:
Baseline: n = 64
Week 24: n = 52
Week 48: n = 48

[183] - Safety Population
Number of subjects at visit:
Baseline: n = 62
Week 24: n = 55
Week 48: n = 50

[184] - Safety Population
Number of subjects at visit:
Baseline: n = 62
Week 24: n = 49
Week 48: n = 39

End point values	ALX-0061 225 mg q2w			
Subject group type	Reporting group			
Number of subjects analysed	62[185]			
Units: IU/mL				
arithmetic mean (standard error)				
Baseline	73.34 (± 25.940)			
Week 24	23.25 (± 6.417)			
Week 48	15.53 (± 6.069)			

Notes:

[185] - Safety Population
Number of subjects at visit:
Baseline: n = 62
Week 24: n = 53
Week 48: n = 46

Statistical analyses

No statistical analyses for this end point

Secondary: Actual values of complement C3 concentrations at Baseline, Week 24, and Week 48

End point title	Actual values of complement C3 concentrations at Baseline, Week 24, and Week 48

End point description:

End point type	Secondary

End point timeframe:

At Baseline, Week 24, and Week 48

End point values	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w	ALX-0061 150 mg q2w
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62[186]	64[187]	62[188]	62[189]
Units: mg/dL				
arithmetic mean (standard error)				
Baseline	102.3 (± 3.82)	100.2 (± 4.12)	101.9 (± 3.79)	105.8 (± 4.38)
Week 24	101.7 (± 4.30)	95.7 (± 3.81)	82.0 (± 3.68)	75.3 (± 2.90)
Week 48	95.8 (± 4.25)	93.2 (± 4.20)	79.0 (± 3.25)	83.2 (± 3.18)

Notes:

[186] - Safety Population
Number of subjects at visit:
Baseline: n = 62
Week 24: n = 55
Week 48: n = 53

[187] - Safety Population
Number of subjects at visit:
Baseline: n = 64
Week 24: n = 52
Week 48: n = 48

[188] - Safety Population
Number of subjects at visit:
Baseline: n = 62
Week 24: n = 55
Week 48: n = 50

[189] - Safety Population
Number of subjects at visit:
Baseline: n = 62
Week 24: n = 47
Week 48: n = 38

End point values	ALX-0061 225 mg q2w			
Subject group type	Reporting group			
Number of subjects analysed	62[190]			
Units: mg/dL				
arithmetic mean (standard error)				
Baseline	98.6 (± 3.98)			
Week 24	71.8 (± 2.82)			
Week 48	72.3 (± 2.61)			

Notes:

[190] - Safety Population
Number of subjects at visit:
Baseline: n = 62
Week 24: n = 52
Week 48: n = 45

Statistical analyses

No statistical analyses for this end point

Secondary: Actual values of complement C4 concentrations at Baseline, Week 24, and Week 48

End point title	Actual values of complement C4 concentrations at Baseline, Week 24, and Week 48

End point description:

End point type	Secondary

End point timeframe:
At Baseline, Week 24, and Week 48

End point values	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w	ALX-0061 150 mg q2w
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62[191]	64[192]	62[193]	62[194]
Units: mg/dL				
arithmetic mean (standard error)				
Baseline	17.3 (± 1.08)	17.8 (± 1.07)	15.9 (± 0.96)	18.7 (± 1.19)
Week 24	17.5 (± 1.09)	17.4 (± 1.10)	10.6 (± 0.85)	8.7 (± 0.40)
Week 48	16.3 (± 1.15)	17.3 (± 1.27)	10.5 (± 0.84)	9.8 (± 0.89)

Notes:

[191] - Safety Population
Number of subjects at visit:
Baseline: n = 62
Week 24: n = 54
Week 48: n = 52

[192] - Safety Population
Number of subjects at visit:
Baseline: n = 64
Week 24: n = 52
Week 48: n = 47

[193] - Safety Population
Number of subjects at visit:
Baseline: n = 62
Week 24: n = 55
Week 48: n = 48

[194] - Safety Population
Number of subjects at visit:
Baseline: n = 62
Week 24: n = 47
Week 48: n = 38

End point values	ALX-0061 225 mg q2w			
Subject group type	Reporting group			
Number of subjects analysed	62[195]			
Units: mg/dL				
arithmetic mean (standard error)				
Baseline	16.3 (± 1.04)			
Week 24	7.9 (± 0.37)			
Week 48	8.1 (± 0.41)			

Notes:

[195] - Safety Population
Number of subjects at visit:
Baseline: n = 62
Week 24: n = 52
Week 48: n = 43

Statistical analyses

No statistical analyses for this end point

Secondary: Actual values for hemolytic complement component 50 (CH50) at Baseline, Week 24, and Week 48

End point title	Actual values for hemolytic complement component 50 (CH50) at Baseline, Week 24, and Week 48

End point description:

End point type	Secondary

End point timeframe:

At Baseline, Week 24, and Week 48

End point values	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w	ALX-0061 150 mg q2w
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62[196]	64[197]	62[198]	62[199]
Units: unit(s)				
arithmetic mean (standard error)				
Baseline	101.1 (± 7.46)	109.6 (± 8.83)	98.9 (± 6.95)	103.0 (± 7.47)
Week 24	95.8 (± 7.94)	107.0 (± 7.08)	73.6 (± 6.94)	56.7 (± 4.91)
Week 48	102.2 (± 8.38)	113.1 (± 8.63)	73.5 (± 8.26)	68.4 (± 6.95)

Notes:

[196] - Safety Population
Number of subjects at visit:
Baseline: n = 62
Week 24: n = 56
Week 48: n = 54

[197] - Safety Population
Number of subjects at visit:
Baseline: n = 64
Week 24: n = 52
Week 48: n = 48

[198] - Safety Population
Number of subjects at visit:
Baseline: n = 62
Week 24: n = 56
Week 48: n = 50

[199] - Safety Population
Number of subjects at visit:
Baseline: n = 62
Week 24: n = 49
Week 48: n = 39

End point values	ALX-0061 225 mg q2w			
Subject group type	Reporting group			
Number of subjects analysed	62[200]			
Units: unit(s)				
arithmetic mean (standard error)				
Baseline	82.4 (± 7.09)			
Week 24	41.1 (± 3.63)			
Week 48	41.9 (± 3.32)			

Notes:

[200] - Safety Population
Number of subjects at visit:
Baseline: n = 62
Week 24: n = 53
Week 48: n = 46

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of subjects who were treatment-emergent (TE) anti-drug antibody (ADA) positive

End point title	Proportion of subjects who were treatment-emergent (TE) anti-drug antibody (ADA) positive

End point description:

End point type	Secondary

End point timeframe:

From first administration of ALX-0061 up to and including follow-up

End point values	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w	ALX-0061 150 mg q2w
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62[201]	64[202]	62[203]	62[204]
Units: Percent	52	25	29	50

Notes:

[201] - Safety Population

[202] - Safety Population

[203] - Safety Population

[204] - Safety Population

End point values	ALX-0061 225 mg q2w			
Subject group type	Reporting group			
Number of subjects analysed	62[205]			
Units: Percent	61			

Notes:

[205] - Safety Population

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information	
Timeframe for reporting adverse events: From obtaining signed and dated informed consent form (ICF) until completion of the subject's last visit.	
Assessment type	Systematic
Dictionary used	
Dictionary name	MedDRA
Dictionary version	20.1
Reporting groups	
Reporting group title	Placebo
Reporting group description: Two subcutaneous injections with placebo every two weeks	
Reporting group title	ALX-0061 75 mg q4w
Reporting group description: ALX-0061 75 mg every 4 weeks	
Reporting group title	ALX-0061 150 mg q4w
Reporting group description: ALX-0061 150 mg every 4 weeks	
Reporting group title	ALX-0061 150 mg q2w
Reporting group description: ALX-0061 150 mg every 2 weeks	
Reporting group title	ALX-0061 225 mg q2w
Reporting group description: ALX-0061 225 mg every 2 weeks	

Serious adverse events	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w
Total subjects affected by serious adverse events			
subjects affected / exposed	7 / 62 (11.29%)	2 / 64 (3.13%)	4 / 62 (6.45%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 62 (0.00%)	0 / 64 (0.00%)	0 / 62 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vasculitis			
subjects affected / exposed	0 / 62 (0.00%)	0 / 64 (0.00%)	0 / 62 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration			

site conditions			
Pyrexia			
subjects affected / exposed	1 / 62 (1.61%)	0 / 64 (0.00%)	0 / 62 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Allergy to arthropod sting			
subjects affected / exposed	0 / 62 (0.00%)	0 / 64 (0.00%)	1 / 62 (1.61%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Pulmonary embolismy			
subjects affected / exposed	0 / 62 (0.00%)	0 / 64 (0.00%)	0 / 62 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 62 (0.00%)	0 / 64 (0.00%)	0 / 62 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Depression			
subjects affected / exposed	1 / 62 (1.61%)	0 / 64 (0.00%)	0 / 62 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicidal ideation			
subjects affected / exposed	0 / 62 (0.00%)	0 / 64 (0.00%)	0 / 62 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicide attempt			
subjects affected / exposed	0 / 62 (0.00%)	0 / 64 (0.00%)	0 / 62 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Ligament rupture			

subjects affected / exposed	1 / 62 (1.61%)	0 / 64 (0.00%)	0 / 62 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ligament sprain			
subjects affected / exposed	1 / 62 (1.61%)	0 / 64 (0.00%)	0 / 62 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post-traumatic pain			
subjects affected / exposed	0 / 62 (0.00%)	0 / 64 (0.00%)	1 / 62 (1.61%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxicity to various agents			
subjects affected / exposed	0 / 62 (0.00%)	0 / 64 (0.00%)	0 / 62 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Cardiopulmonary failure			
subjects affected / exposed	0 / 62 (0.00%)	0 / 64 (0.00%)	0 / 62 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Generalised tonic-clonic seizure			
subjects affected / exposed	0 / 62 (0.00%)	1 / 64 (1.56%)	0 / 62 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxic-ischaemic encephalopathy			
subjects affected / exposed	0 / 62 (0.00%)	0 / 64 (0.00%)	0 / 62 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 62 (0.00%)	0 / 64 (0.00%)	0 / 62 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			

Anaemia of chronic disease			
subjects affected / exposed	0 / 62 (0.00%)	0 / 64 (0.00%)	0 / 62 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombotic thrombocytopenic purpura			
subjects affected / exposed	1 / 62 (1.61%)	0 / 64 (0.00%)	0 / 62 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Open angle glaucoma			
subjects affected / exposed	0 / 62 (0.00%)	0 / 64 (0.00%)	1 / 62 (1.61%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Gastric ulcer			
subjects affected / exposed	1 / 62 (1.61%)	0 / 64 (0.00%)	0 / 62 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis chronic			
subjects affected / exposed	0 / 62 (0.00%)	0 / 64 (0.00%)	0 / 62 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	0 / 62 (0.00%)	0 / 64 (0.00%)	0 / 62 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Rotator cuff syndrome			
subjects affected / exposed	0 / 62 (0.00%)	0 / 64 (0.00%)	0 / 62 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Cellulitis			

subjects affected / exposed	0 / 62 (0.00%)	0 / 64 (0.00%)	1 / 62 (1.61%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	2 / 62 (3.23%)	0 / 64 (0.00%)	0 / 62 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinusitis			
subjects affected / exposed	1 / 62 (1.61%)	0 / 64 (0.00%)	1 / 62 (1.61%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytomegalovirus infection			
subjects affected / exposed	1 / 62 (1.61%)	0 / 64 (0.00%)	0 / 62 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erysipelas			
subjects affected / exposed	0 / 62 (0.00%)	0 / 64 (0.00%)	1 / 62 (1.61%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis			
subjects affected / exposed	0 / 62 (0.00%)	1 / 64 (1.56%)	0 / 62 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonsillar abscess			
subjects affected / exposed	0 / 62 (0.00%)	0 / 64 (0.00%)	0 / 62 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary tuberculoma			
subjects affected / exposed	0 / 62 (0.00%)	0 / 64 (0.00%)	0 / 62 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous abscess			

subjects affected / exposed	0 / 62 (0.00%)	0 / 64 (0.00%)	1 / 62 (1.61%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tuberculous pleurisy			
subjects affected / exposed	0 / 62 (0.00%)	0 / 64 (0.00%)	0 / 62 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	ALX-0061 150 mg q2w	ALX-0061 225 mg q2w	
Total subjects affected by serious adverse events			
subjects affected / exposed	5 / 62 (8.06%)	5 / 62 (8.06%)	
number of deaths (all causes)	2	0	
number of deaths resulting from adverse events	2	0	
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 62 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vasculitis			
subjects affected / exposed	0 / 62 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	0 / 62 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Allergy to arthropod sting			
subjects affected / exposed	0 / 62 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Pulmonary embolismy			

subjects affected / exposed	1 / 62 (1.61%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory failure			
subjects affected / exposed	1 / 62 (1.61%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Depression			
subjects affected / exposed	0 / 62 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Suicidal ideation			
subjects affected / exposed	1 / 62 (1.61%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Suicide attempt			
subjects affected / exposed	1 / 62 (1.61%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Ligament rupture			
subjects affected / exposed	0 / 62 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ligament sprain			
subjects affected / exposed	0 / 62 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post-traumatic pain			
subjects affected / exposed	0 / 62 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Toxicity to various agents			
subjects affected / exposed	1 / 62 (1.61%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Cardiopulmonary failure			
subjects affected / exposed	1 / 62 (1.61%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
Nervous system disorders			
Generalised tonic-clonic seizure			
subjects affected / exposed	0 / 62 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoxic-ischaemic encephalopathy			
subjects affected / exposed	1 / 62 (1.61%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seizure			
subjects affected / exposed	1 / 62 (1.61%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Blood and lymphatic system disorders			
Anaemia of chronic disease			
subjects affected / exposed	1 / 62 (1.61%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombotic thrombocytopenic purpura			
subjects affected / exposed	0 / 62 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Open angle glaucoma			

subjects affected / exposed	0 / 62 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Gastric ulcer			
subjects affected / exposed	0 / 62 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis chronic			
subjects affected / exposed	0 / 62 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	1 / 62 (1.61%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Rotator cuff syndrome			
subjects affected / exposed	0 / 62 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Cellulitis			
subjects affected / exposed	0 / 62 (0.00%)	2 / 62 (3.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	1 / 62 (1.61%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinusitis			

subjects affected / exposed	0 / 62 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cytomegalovirus infection			
subjects affected / exposed	0 / 62 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erysipelas			
subjects affected / exposed	0 / 62 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningitis			
subjects affected / exposed	0 / 62 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritonsillar abscess			
subjects affected / exposed	1 / 62 (1.61%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary tuberculoma			
subjects affected / exposed	1 / 62 (1.61%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subcutaneous abscess			
subjects affected / exposed	0 / 62 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tuberculous pleurisy			
subjects affected / exposed	1 / 62 (1.61%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Placebo	ALX-0061 75 mg q4w	ALX-0061 150 mg q4w
Total subjects affected by non-serious adverse events			
subjects affected / exposed	40 / 62 (64.52%)	41 / 64 (64.06%)	31 / 62 (50.00%)
Investigations			
Hepatic enzyme increased			
subjects affected / exposed	0 / 62 (0.00%)	0 / 64 (0.00%)	1 / 62 (1.61%)
occurrences (all)	0	0	1
Vascular disorders			
Hypertension			
subjects affected / exposed	4 / 62 (6.45%)	2 / 64 (3.13%)	3 / 62 (4.84%)
occurrences (all)	4	2	4
Nervous system disorders			
Headache			
subjects affected / exposed	13 / 62 (20.97%)	4 / 64 (6.25%)	3 / 62 (4.84%)
occurrences (all)	16	27	4
General disorders and administration site conditions			
Injection site erythema			
subjects affected / exposed	0 / 62 (0.00%)	2 / 64 (3.13%)	2 / 62 (3.23%)
occurrences (all)	0	3	5
Injection site rash			
subjects affected / exposed	0 / 62 (0.00%)	3 / 64 (4.69%)	1 / 62 (1.61%)
occurrences (all)	0	3	1
Injection site reaction			
subjects affected / exposed	0 / 62 (0.00%)	0 / 64 (0.00%)	0 / 62 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Neutropenia			
subjects affected / exposed	2 / 62 (3.23%)	3 / 64 (4.69%)	3 / 62 (4.84%)
occurrences (all)	2	6	3
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	6 / 62 (9.68%)	1 / 64 (1.56%)	0 / 62 (0.00%)
occurrences (all)	6	1	0
Nausea			

subjects affected / exposed	4 / 62 (6.45%)	1 / 64 (1.56%)	2 / 62 (3.23%)
occurrences (all)	6	1	2
Skin and subcutaneous tissue disorders			
Urticaria			
subjects affected / exposed	0 / 62 (0.00%)	1 / 64 (1.56%)	4 / 62 (6.45%)
occurrences (all)	0	1	6
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	4 / 62 (6.45%)	2 / 64 (3.13%)	1 / 62 (1.61%)
occurrences (all)	5	2	1
Infections and infestations			
Urinary tract infection			
subjects affected / exposed	8 / 62 (12.90%)	5 / 64 (7.81%)	7 / 62 (11.29%)
occurrences (all)	11	10	10
Upper respiratory tract infection			
subjects affected / exposed	5 / 62 (8.06%)	5 / 64 (7.81%)	5 / 62 (8.06%)
occurrences (all)	5	7	5
Nasopharyngitis			
subjects affected / exposed	6 / 62 (9.68%)	6 / 64 (9.38%)	5 / 62 (8.06%)
occurrences (all)	8	7	6
Bronchitis			
subjects affected / exposed	2 / 62 (3.23%)	2 / 64 (3.13%)	4 / 62 (6.45%)
occurrences (all)	3	3	4
Sinusitis			
subjects affected / exposed	2 / 62 (3.23%)	3 / 64 (4.69%)	0 / 62 (0.00%)
occurrences (all)	3	6	0

Non-serious adverse events	ALX-0061 150 mg q2w	ALX-0061 225 mg q2w	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	47 / 62 (75.81%)	50 / 62 (80.65%)	
Investigations			
Hepatic enzyme increased			
subjects affected / exposed	6 / 62 (9.68%)	0 / 62 (0.00%)	
occurrences (all)	6	0	
Vascular disorders			
Hypertension			

subjects affected / exposed	3 / 62 (4.84%)	1 / 62 (1.61%)	
occurrences (all)	3	1	
Nervous system disorders			
Headache			
subjects affected / exposed	3 / 62 (4.84%)	10 / 62 (16.13%)	
occurrences (all)	6	10	
General disorders and administration site conditions			
Injection site erythema			
subjects affected / exposed	5 / 62 (8.06%)	5 / 62 (8.06%)	
occurrences (all)	17	11	
Injection site rash			
subjects affected / exposed	4 / 62 (6.45%)	3 / 62 (4.84%)	
occurrences (all)	17	6	
Injection site reaction			
subjects affected / exposed	4 / 62 (6.45%)	1 / 62 (1.61%)	
occurrences (all)	5	5	
Blood and lymphatic system disorders			
Neutropenia			
subjects affected / exposed	5 / 62 (8.06%)	6 / 62 (9.68%)	
occurrences (all)	9	7	
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	1 / 62 (1.61%)	2 / 62 (3.23%)	
occurrences (all)	1	2	
Nausea			
subjects affected / exposed	2 / 62 (3.23%)	0 / 62 (0.00%)	
occurrences (all)	2	0	
Skin and subcutaneous tissue disorders			
Urticaria			
subjects affected / exposed	1 / 62 (1.61%)	2 / 62 (3.23%)	
occurrences (all)	1	2	
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	1 / 62 (1.61%)	0 / 62 (0.00%)	
occurrences (all)	1	0	
Infections and infestations			

Urinary tract infection			
subjects affected / exposed	3 / 62 (4.84%)	8 / 62 (12.90%)	
occurrences (all)	5	12	
Upper respiratory tract infection			
subjects affected / exposed	5 / 62 (8.06%)	3 / 62 (4.84%)	
occurrences (all)	8	5	
Nasopharyngitis			
subjects affected / exposed	2 / 62 (3.23%)	1 / 62 (1.61%)	
occurrences (all)	3	1	
Bronchitis			
subjects affected / exposed	2 / 62 (3.23%)	1 / 62 (1.61%)	
occurrences (all)	2	1	
Sinusitis			
subjects affected / exposed	4 / 62 (6.45%)	1 / 62 (1.61%)	
occurrences (all)	4	1	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
07 May 2015	Protocol Version 2 The changes are summarized as follows: • Inclusion criterion 1 was updated to take into account differences in the definition of adult age between countries and regions. • Exclusion criterion 1 was updated to clarify which assessment result (screening) was to be considered for eligibility. • Wording regarding the terms background and rescue medication was changed to clarify that these referred to the standard of care medication as per local practice or a change of this medication. • A discontinuation criterion was updated to clarify that discontinuation of study drug administration was to be considered in cases where subjects experienced renal or CNS flare. • The schedule of assessments was updated to clarify that CLASI and exploratory biomarkers were also to be assessed at the time of early termination. • The assessment of ESR was removed from the protocol for the following reasons: 1) This was not an essential parameter needed for the planned analysis, 2) Other parameters (CRP, fibrinogen) that reflected the inflammation status of the subject were measured, and 3) Unblinding of the treatment when ESR was locally assessed and reported by study staff could be avoided. • For pregnancy testing, it was clarified that if local regulations required more frequent pregnancy testing, this was to be applied. • The wording on laboratory re-tests was updated to differentiate between re-test at screening and re-tests during the study. • The statement "SUSARs that are already present in the European Medicines Agency EudraVigilance database do not have to be once again reported to the Competent Authority because they have direct access to the EudraVigilance database" was deleted, as it only applied in European countries and this study was also conducted in non-EU countries. • The text in the section regarding follow-up of AEs was updated to clarify that all AEs were to be followed until satisfactory outcome.

03 May 2016	Protocol Version 3 The main changes are summarized as follows: • Inclusion criterion 2 was clarified to reflect that the diagnosis of SLE should have occurred at least 6 months prior to screening and that at screening the ACR and/or SLICC criteria needed to be fulfilled. • The dose of the allowed medication mycophenolate mofetil was updated from a maximum of 1.5 g/d to 2.0 g/d to allow the inclusion of subjects who were receiving the usual dose for SLE patients. The units of MTX and cyclosporine dosing regimens were corrected or further specified. • Wording was updated to specify that exclusion criterion 1: an A score on the revised BILAG-2004, not only applied to the screening assessment but also at baseline for the organ systems that could have been clinically assessed at that time point. Exclusion criterion 3 was updated to clarify that subjects with clinically non-significant infections could have been enrolled in the study, and exclusion criterion 7 was updated for clarification purposes. • The description of the analysis of the primary efficacy endpoint was expanded to specify that only subjects who discontinued before Week 24 were to be treated as non-responders for this endpoint at this time point. • Wording was added to clarify that after Week 24, the dose of NSAIDs could have been adjusted based on the Investigator's discretion. • Wording was added to clarify that the Investigator may decide to interrupt study drug treatment for 1 dose according to his/her medical judgment because of an AE. • The laboratory parameter CPK was added to the list of biochemistry parameters being analyzed, and creatinine was added to the list of urinalysis parameters. Wording was added to accurately reflect what was to be tested when screening for hepatitis and to clarify that additional pregnancy testing could have been done. Clarifications were added to statements regarding the follow-up of unexplained or unexpected clinical laboratory tests.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported